Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000921895-25-001483
Filing Date
2025-05-14
Accepted
2025-05-14 20:26:02
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 13394
2 JOINT FILING AGREEMENT ex991to13g10925rntx_051425.htm EX-99.1 7989
  Complete submission text file 0000921895-25-001483.txt   23448
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Subject) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90032 | Film No.: 25948054
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3773 RICHMOND AVENUE SUITE 500 HOUSTON TX 77046
Business Address 3773 RICHMOND AVENUE SUITE 500 HOUSTON TX 77046 832-519-9427
Voss Capital, LP (Filed by) CIK: 0001730145 (see all company filings)

EIN.: 000000000 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13G